CClinicalTrials.gg
CompletedNCT03293368Updated Feb 9, 2023

Efficacy of Intralesional Injection of Platelet Rich Plasma in the Treatment of Patients With Erosive Oral Lichen Planus

A Phase 2 interventional study of Platelet rich plasma and Triamcinolone Acetonide in Erosive Oral Lichen Planus, sponsored by Cairo University. Completed at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2023-02-09.

Sponsored by Cairo University · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Sex
All
01

Study summary

After signing the informed consent, the participant will be allocated to either intervention or control group, then each participant in the intervention group will receive intralesional injections of platelet rich plasma extracted from their own blood in each visit as following:

  1. 12 ml of blood will be assembled from the veins of antecubital fossa
  2. PRP preparation will be done according to Mostafa et al., 2013
  3. 0.5 ml of PRP will be injected per 1 cm2 of ulcerated mucosa

The second group will receive triamcinolone acetonide 40 mg injected 1 ml per 1 cm2 of ulcerated mucosa

Both groups will receive a total of 4 injection, the injections will be carried out once a week.

Pain, lesions size and remission time are the outcomes will be assessed using a numerical rating scale (Seymour, 1982), clinical score according to Thongprasom et al., 1992 and binary scale for remission time according to Conrotto et al., 2006, respectively.

Assessment of the outcomes will be carried before the trial (baseline records) and before receiving the treatment in each visit by the primary investigator (H.A.) and the blinded assessor (Dr. A.W.) separately.

Each participant will have a total of 11 visits during the trial, 5 visits will be once every week during the trial and every 2 weeks for 3 months treatment free.

02

Conditions studied

  • Erosive Oral Lichen Planus

Keywords

  • Oral
  • Lichen planus
  • PRP
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients presenting with a clinical picture that assumes the diagnosis of erosive oral lichen planus (bilateral, more or less symmetrical erosive lesions with lacelike network of slightly raised gray white lesions (reticular pattern), and a histological findings that confirms the diagnosis (liquefaction degeneration of the basal cell layer with irregular-saw teeth like rete pegs.

Exclusion criteria

Exclusion Criteria:

  • Systemic disorders such as hematological diseases, severe cardiovascular diseases, treatment with any drugs that could cause Lichenoid reaction.
  • Pregnancy or active breastfeeding
  • Patients who had lesion/lesions with dysplasia
  • Patients who received topical treatment for Oral Lichen planus in the last 2 weeks (Lee et al., 2013) or systemic treatment for OLP in the past 3 months.
  • Platelet count \< 150,000/mm3; Hgb \< 11 g/dl.
  • Immunosuppressed patients
  • Patients receiving therapy with anticoagulants and use of non-steroidal anti-inflammatory drugs in the 5 days before taking the blood sample.
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Platelet rich plasma

    0.5 ml of autologous platelet rich plasma prepared using a double spin technique described by Mostafa et al., 2013 will be injected in the center of eroded oral mucosa in patients suffering from oral lichen planus.

    Biological: Platelet rich plasma

  • Active comparator
    Croticosteroids

    0.5 ml of triamcinolone acetonide 40 mg will be injected in the center of eroded oral mucosa in patients suffering from oral lichen planus.

    Drug: Triamcinolone Acetonide

Interventions

  • BiologicalPlatelet rich plasma

    Platelet rich plasma will be prepared from the patients own blood in the same visit using a double spin technique, then 0.5 ml of PRP will be injected per 1 cm2 of eroded oral mucosa.

    Also known as: Platelet rich in growth factors

  • DrugTriamcinolone Acetonide

    0.5 ml of triamcinolone acetonide 40mg will be injected per 1 cm2 of eroded oral mucosa

    Also known as: Corticosteroids, Steroids

05

What researchers measure

Primary outcomes

  1. Reported Pain

    Pain and burning sensation assessed using Numerical rating scale

    Time frame: 3 months

Secondary outcomes

  1. Clinical score

    Clinical score using a 5 grades scoring system described by Thongprasom et al.,1992

    Time frame: 3 months

  2. Remission time

    Time until flare up of the disease occur using a binary scale (Stable/Not stable) described by Conrotto et al., 2006

    Time frame: 3 months

06

Study locations

1 site
  • Faculty of Dentistry
    Cairo, Egypt
07

References and documents

Publications

  • Hijazi A, Ahmed W, Gaafar S. Efficacy of intralesional injections of platelet-rich plasma in patients with oral lichen planus: A pilot randomized clinical trial. Clin Exp Dent Res. 2022 Jun;8(3):707-714. doi: 10.1002/cre2.550. Epub 2022 Feb 26. PubMed 35218680 ↗

Study documents

  • Protocol and statistical analysis plan · Sep 20, 2017

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT03293368
Lead sponsor
Cairo University
Responsible party
Abdelhameed Hamid Mohammad Hijazi (PhD Student, Cairo University) — Principal investigator
First posted
Sep 26, 2017
Start date
Jan 1, 2018
Primary completion
Jan 1, 2021
Completion
Jan 1, 2021
Last update
Feb 9, 2023

Study contacts

Soheir Gaafar, Professor
study chair · Professor of oral medicine, diagnosis and periodontology. Faculty of Dentistry. Cairo University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion